Despite advances in chemotherapy for CLL, this disease remains incurable by standard therapies. Thus, SCT should be considered, especially for younger patients and patients with high-risk genetic features who likely will do poorly with chemotherapy. Non-myeloablative allogeneic SCT is the most promising transplant modality in CLL, and is the focus of most clinical transplant studies in CLL. Short-term DFS of 50-75% has been obtained with acceptable TRM, and molecular responses have been obtained with the onset of GVHD or the therapeutic use of DLI. However, long-term follow-up is lacking, and it is unclear

0 0

Post a comment